Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Players – Takeda, Novartis, Daiichi Sankyo, and Others

Delveinsight Business Research LLP
DelveInsight’s “Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the EGFR-NSCLC Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The EGFR-NSCLC market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer: An Overview

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid Carcinomas.

EGFR is a member of the ErbB family of receptor tyrosine kinases (RTK). Activation of the receptor initiates a cascade of downstream signaling molecules, leading to cell growth and survival. This process is tightly regulated in non-transformed cells. However, constitutive activation of these pathways leads to dysregulated cell growth and proliferation, angiogenesis, and metastasis, while repressing apoptosis. Genomic damage can introduce mutations that mimic kinase activation or result in higher expression levels of EGFR.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Key Facts

The United States had 227,875 incident cases of Lung Cancer in 2020, of which 85% were NSCLC cancer patients.

Among the European 5 countries, the Germany had highest cases of NSCLC.

According to DelveInsight’s assessment, in the United States, 7 out of 10 patients had metastatic NSCLC (Stage IIIb and IV).

The highest number of NSCLC were estimated in the United States.

In histology-specific cases, Adenocarcinoma accounts for the highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.

Estimates show the highest Incident population of EGFR-NSCLC is in the United States, which contributes to around 34% of the total population of EGFR mutated NSCLC in the 7MM (in 2020). Furthermore, among the European 5 countries, Germany had the highest incident population of NSCLC, estimated to be around 29%, which is further followed by the United Kingdom, France, Italy, and Spain. 

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market

EGFR-NSCLC Market is expected to be driven by the increasing incident cases of NSCLC, continue uptake of approved therapies mainly immune checkpoint inhibitors, and expected entry of potential premium price emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted EGFR-NSCLC market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.

The report gives a thorough detail of the EGFR-NSCLC market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Epidemiology

The epidemiology section covers insights about the historical and current EGFR-NSCLC patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Epidemiology Segmentation

Total Incidence of NSCLC

Total Incident cases of NSCLC patients by Histology

Total Diagnosed cases of NSCLC patients by Stages

Total EGFR-NSCLC cases

EGFR-NSCLC Treated cases

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR-NSCLC market or expected to get launched in the market during the study period. The analysis covers the EGFR-NSCLC market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the EGFR-NSCLC Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Therapeutics Analysis

The available therapeutics treatment options in EGFR-NSCLC Landscape aims to provide cures to the patients suffering from this indication, however, there are several challenges that are yet to be tackled.

The dynamics of the EGFR-NSCLC market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in the development of drugs for EGFR-NSCLC. 

Some of the key companies in the EGFR-NSCLC Market include:

Takeda

Novartis

Daiichi Sankyo

Yuhan Corporation/Janssen Research & Development

And many more

EGFR-NSCLC Therapies covered in the report include:

TAK-788 (mobocertinib)

Lazertinib (Leclaza)

Nazartinib (EGF816)

Patritumab deruxtecan (HER3-DXd)

And many others

The positive results of investigational products and a robust pipeline for EGFR-NSCLC bring a positive ray of hope for a better treatment pattern in the market in the coming years. The current scenario also anticipates a positive shift in the market during the study period.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- EGFR-NSCLC Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. EGFR-NSCLC Competitive Intelligence Analysis

4. EGFR-NSCLC Market Overview at a Glance

5. EGFR-NSCLC Disease Background and Overview

6. EGFR-NSCLC Patient Journey

7. EGFR-NSCLC Epidemiology and Patient Population

8. EGFR-NSCLC Treatment Algorithm, Current Treatment, and Medical Practices

9. EGFR-NSCLC Unmet Needs

10. Key Endpoints of EGFR-NSCLC Treatment

11. EGFR-NSCLC Marketed Products

12. EGFR-NSCLC Emerging Therapies

13. EGFR-NSCLC Seven Major Market Analysis

14. Attribute Analysis

15. EGFR-NSCLC Market Outlook (7 major markets)

16. EGFR-NSCLC Access and Reimbursement Overview

17. KOL Views on the EGFR-NSCLC Market.

18. EGFR-NSCLC Market Drivers

19. EGFR-NSCLC Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Latest Blog By DelveInsight

Globally, several major MedTech companies such as Medtronics, Cochlear, Abbott, Boston Scientific, LivaNova, Second Sight Medical Products, MED-EL, Retina Implant, Sonova Group, NeuroPace, and others, are actively working in the Neuroprosthetics segment to create new devices and to provide momentum to the market growth. Dive deep into our blog in order to find out more about the robust expansion in the Neuroprosthetics market at Neuroprosthetics Market Analysis

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/